Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer

R. K. Bikkavilli, S. Avasarala, M. Van Scoyk, J. Arcaroli, C. Brzezinski, W. Zhang, M. G. Edwards, M. K.K. Rathinam, Tong Zhou, J. Tauler, S. Borowicz, Yves A Lussier, B. A. Parr, C. D. Cool, R. A. Winn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of β-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16INK4a and p19ARF pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.Oncogene advance online publication, 2 March 2015; doi:10.1038/onc.2015.2.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Mar 2 2015

Fingerprint

Catenins
Cell Aging
Lung Neoplasms
Neoplasms
Iloprost
Carcinogenesis
Cadherins
Oncogenes
S-Phase Kinase-Associated Proteins
Lung
Autophagy
Epoprostenol
Genetic Predisposition to Disease
Carcinogens
Publications
Apoptosis
Phenotype
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Bikkavilli, R. K., Avasarala, S., Van Scoyk, M., Arcaroli, J., Brzezinski, C., Zhang, W., ... Winn, R. A. (Accepted/In press). Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene. https://doi.org/10.1038/onc.2015.2

Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. / Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Arcaroli, J.; Brzezinski, C.; Zhang, W.; Edwards, M. G.; Rathinam, M. K.K.; Zhou, Tong; Tauler, J.; Borowicz, S.; Lussier, Yves A; Parr, B. A.; Cool, C. D.; Winn, R. A.

In: Oncogene, 02.03.2015.

Research output: Contribution to journalArticle

Bikkavilli, RK, Avasarala, S, Van Scoyk, M, Arcaroli, J, Brzezinski, C, Zhang, W, Edwards, MG, Rathinam, MKK, Zhou, T, Tauler, J, Borowicz, S, Lussier, YA, Parr, BA, Cool, CD & Winn, RA 2015, 'Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer', Oncogene. https://doi.org/10.1038/onc.2015.2
Bikkavilli RK, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W et al. Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene. 2015 Mar 2. https://doi.org/10.1038/onc.2015.2
Bikkavilli, R. K. ; Avasarala, S. ; Van Scoyk, M. ; Arcaroli, J. ; Brzezinski, C. ; Zhang, W. ; Edwards, M. G. ; Rathinam, M. K.K. ; Zhou, Tong ; Tauler, J. ; Borowicz, S. ; Lussier, Yves A ; Parr, B. A. ; Cool, C. D. ; Winn, R. A. / Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. In: Oncogene. 2015.
@article{196f748467f541fb96c6ab7f0f7f9bfb,
title = "Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer",
abstract = "Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of β-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16INK4a and p19ARF pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.Oncogene advance online publication, 2 March 2015; doi:10.1038/onc.2015.2.",
author = "Bikkavilli, {R. K.} and S. Avasarala and {Van Scoyk}, M. and J. Arcaroli and C. Brzezinski and W. Zhang and Edwards, {M. G.} and Rathinam, {M. K.K.} and Tong Zhou and J. Tauler and S. Borowicz and Lussier, {Yves A} and Parr, {B. A.} and Cool, {C. D.} and Winn, {R. A.}",
year = "2015",
month = "3",
day = "2",
doi = "10.1038/onc.2015.2",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer

AU - Bikkavilli, R. K.

AU - Avasarala, S.

AU - Van Scoyk, M.

AU - Arcaroli, J.

AU - Brzezinski, C.

AU - Zhang, W.

AU - Edwards, M. G.

AU - Rathinam, M. K.K.

AU - Zhou, Tong

AU - Tauler, J.

AU - Borowicz, S.

AU - Lussier, Yves A

AU - Parr, B. A.

AU - Cool, C. D.

AU - Winn, R. A.

PY - 2015/3/2

Y1 - 2015/3/2

N2 - Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of β-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16INK4a and p19ARF pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.Oncogene advance online publication, 2 March 2015; doi:10.1038/onc.2015.2.

AB - Cellular senescence is an initial barrier for carcinogenesis. However, the signaling mechanisms that trigger cellular senescence are incompletely understood, particularly in vivo. Here we identify Wnt7a as a novel upstream inducer of cellular senescence. In two different mouse strains (C57Bl/6J and FVB/NJ), we show that the loss of Wnt7a is a major contributing factor for increased lung tumorigenesis owing to reduced cellular senescence, and not reduced apoptosis, or autophagy. Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. Interestingly, Wnt7a induced an alternate senescence pathway, which was independent of β-catenin, and distinct from that of classical oncogene-induced senescence mediated by the well-known p16INK4a and p19ARF pathways. Mechanistically, Wnt7a induced cellular senescence via inactivation of S-phase kinase-associated protein 2, an important alternate regulator of cellular senescence. Additionally, we identified Iloprost, a prostacyclin analog, which initiates downstream signaling cascades similar to that of Wnt7a, as a novel inducer of cellular senescence, presenting potential future clinical translational strategies. Thus pro-senescence therapies using either Wnt7a or its mimic, Iloprost, might represent a new class of therapeutic treatments for lung cancer.Oncogene advance online publication, 2 March 2015; doi:10.1038/onc.2015.2.

UR - http://www.scopus.com/inward/record.url?scp=84923925067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923925067&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.2

DO - 10.1038/onc.2015.2

M3 - Article

C2 - 25728679

AN - SCOPUS:84945446792

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -